Fleseriu M, Langlois F, Lim DST, et al. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10(11):804–26.

Article  CAS  PubMed  Google Scholar 

McLaren DS, Seejore K, Lynch J, et al. Oral octreotide capsules and paltusotine in management of acromegaly. touchREV Endocrinol. 2024;20(1):32–6.

PubMed  Google Scholar 

Crinetics Pharmaceuticals, Inc,. Crinetics announces FDA approval of PALSONIFY™ (paltusotine) for the treatment of acromegaly in adults [media release]. 25 Sep 2025. https://crinetics.com/.

Crinetics Pharmaceuticals, Inc. PALSONIFY (paltusotine) tablets: US prescribing information. 2025. https://crinetics.com/PALSONIFY_PI/. Accessed 2 Oct 2025.

Crinetics P. Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho enter into exclusive licensing agreement for the development and commercialization of paltusotine in Japan [media release]. 28 Feb 2022. http://www.crinetics.com.

Madan A, Markison S, Betz SF, et al. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers. Pituitary. 2022;25(2):328–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gadelha MR, Casagrande A, Strasburger CJ, et al. Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine. J Clin Endocrinol Metab. 2024;110(1):228–37.

Article  PubMed  PubMed Central  Google Scholar 

Biller BM, Casagrande A, Elenkova A, et al. Efficacy and safety of once-daily oral paltusotine In medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled PATHFNDR-2 study [abstract no. 12535 plus Poster]. J Endocr Soc. 2024;8(Suppl. 1):A625–6.

Google Scholar 

Rizio AA, Carty MK, Krasner A, et al. Effects of paltusotine treatment on patient-reported symptoms of acromegaly in phase 3 randomized placebo-controlled studies (PATHFNDR-1 and PATHFNDR-2) [abstract no. SUN-052]. In: Endocrine Society Annual Meeting (ENDO). 2025.

Gadelha MR, Casagrande A, Elenkova A, et al. Once-daily oral paltusotine in the treatment of patients with biochemically uncontrolled acromegaly: interim results of the PATHFNDR-2 open-label extension [abstract no. MON-069]. In: Endocrine Society Annual Meeting (ENDO). 2025.

Biller BMK, Casagrande A, Strasburger CJ, et al. Disease control in patients with acromegaly switching from injected somatostatin receptor ligands to once-daily oral paltusotine: interim results of the PATHFNDR-1 open-label extension [abstract plus Presentation]. In: Endocrine Society Annual Meeting (ENDO). 2025.

Gadelha MR, Gordon MB, Doknic M, et al. Acrobat edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly. J Clin Endocrinol Metab. 2023;108(5):e148–59.

Article  PubMed  Google Scholar 

Gadelha MR, Randeva HS, Gordon MB, et al. Long-term safety and efficacy of once-daily oral paltusotine in the treatment of patients with acromegaly: ACROBAT advance year 4 analysis [abstract no. P973]. In: Endocrine Abstracts. 2025.

Chauhan A, Mohamed A, Usiskin K, et al. Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: results from a phase 2, randomized, parallel-group study [abstract no. ID28555]. In: Endocrine Abstracts. 2024.